I personally wouldn't lose a second's sleep worrying about SNGX's drug stealing the market from Brilacidin-OM. Just take a look at their 5 year stock chart. They are in a viscous financing deal with Lincoln Park. If SGX942 is their best drug, they are in deep doodoo. Take a look at slide 41. If they give more of the drug it stops working? Not exactly the dose dependent response that one would hope for. At its best it still doesn't even prevent severe OM just reduces the duration by 50%.

I myself would just be happy if B-OM works at the interim review, so they can use it as part of the proof that Brilacidin will be effective for UC. That's where the market is willing to pony up big bucks for a new effective treatment especially since the UP trial indicates it's not absorbed systemically through the mucosa.






5 year chart

https://www.google.com/search?q=marketcap%20s...p;oe=utf-8